MX352245B - Formulacion farmaceutica que comprende una droga biofarmaceutica. - Google Patents

Formulacion farmaceutica que comprende una droga biofarmaceutica.

Info

Publication number
MX352245B
MX352245B MX2013007537A MX2013007537A MX352245B MX 352245 B MX352245 B MX 352245B MX 2013007537 A MX2013007537 A MX 2013007537A MX 2013007537 A MX2013007537 A MX 2013007537A MX 352245 B MX352245 B MX 352245B
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
biopharmaceutical drug
biopharmaceutical
drug
backbone
Prior art date
Application number
MX2013007537A
Other languages
English (en)
Other versions
MX2013007537A (es
Inventor
Martina Danek-Bulius
Britta Deutel
Sabine Fürtinger
Bernt Pragl
Drago Kuzman
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of MX2013007537A publication Critical patent/MX2013007537A/es
Publication of MX352245B publication Critical patent/MX352245B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica que comprende una droga biofarmacéutica, donde dicha composición además comprende por lo menos un ácido mono- o dicarboxílico con un esqueleto principal de 2 - 6 átomos de C, o por lo menos una sal del mismo (Figura 4a).
MX2013007537A 2010-12-28 2011-12-28 Formulacion farmaceutica que comprende una droga biofarmaceutica. MX352245B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10197122A EP2471554A1 (en) 2010-12-28 2010-12-28 Pharmaceutical formulation comprising a biopharmaceutical drug
PCT/EP2011/074181 WO2012089778A1 (en) 2010-12-28 2011-12-28 Pharmaceutical formulation comprising a biopharmaceutical drug

Publications (2)

Publication Number Publication Date
MX2013007537A MX2013007537A (es) 2014-03-13
MX352245B true MX352245B (es) 2017-10-31

Family

ID=43982272

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007537A MX352245B (es) 2010-12-28 2011-12-28 Formulacion farmaceutica que comprende una droga biofarmaceutica.

Country Status (22)

Country Link
US (1) US9480743B2 (es)
EP (2) EP2471554A1 (es)
JP (2) JP5767340B2 (es)
KR (1) KR101808367B1 (es)
CN (1) CN103269718B (es)
AR (2) AR084627A1 (es)
AU (1) AU2011351414B2 (es)
BR (1) BR112013016770A2 (es)
CA (1) CA2822859C (es)
DK (1) DK2658575T3 (es)
ES (1) ES2659981T3 (es)
HR (1) HRP20171931T1 (es)
HU (1) HUE035707T2 (es)
MX (1) MX352245B (es)
NO (1) NO2658575T3 (es)
PL (1) PL2658575T3 (es)
PT (1) PT2658575T (es)
RU (1) RU2587056C2 (es)
SI (1) SI2658575T1 (es)
TW (1) TWI530295B (es)
WO (1) WO2012089778A1 (es)
ZA (2) ZA201304446B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
JP2015509526A (ja) 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド 医薬製剤
US20130236505A1 (en) 2012-03-09 2013-09-12 Basf Se Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment
WO2013186230A1 (en) * 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
AU2013312300A1 (en) 2012-09-07 2015-04-16 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
WO2014100143A2 (en) * 2012-12-20 2014-06-26 Medimmune, Llc Liquid antibody formulation with improved aggregation properties
CN103446583B (zh) * 2013-03-21 2015-11-18 百奥泰生物科技(广州)有限公司 一种治疗TNF-α相关疾病的人抗体制剂
EP3021833B2 (en) * 2013-07-19 2022-03-30 Hexal Aktiengesellschaft Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
HUE029849T2 (en) 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
JP2026501288A (ja) 2022-12-21 2026-01-14 フォーマイコン アーゲー 抗ｐｄ１抗体の製剤
WO2025149960A1 (en) * 2024-01-11 2025-07-17 Lupin Limited Pharmaceutical formulation of anti-il-5 antibody

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US5264142A (en) 1991-11-25 1993-11-23 Lever Brothers Company, Division Of Conopco, Inc. Stabilization of peroxygen bleach in enzyme-containing heavy duty liquids
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
AU2440197A (en) * 1996-04-18 1997-11-07 Baxter International Inc. Stabilization of therapeutic hemoglobin compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7087248B2 (en) * 2000-06-30 2006-08-08 Daiichi Asubio Pharma Co., Ltd. Pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration comprising the component
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
JP2005515180A (ja) * 2001-11-13 2005-05-26 ザ プロクター アンド ギャンブル カンパニー 阻害物質で安定化させた酵素を含有する局所適用組成物
ATE306810T1 (de) 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
US20030204861A1 (en) 2002-04-30 2003-10-30 Madaiah Puttaraju Transgenic animal model for spliceosome-mediated RNA trans-splicing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
AU2003301761A1 (en) * 2002-10-29 2004-05-25 Medical Nutrition Usa, Inc. Method for treating wounds to promote healing
US20040101939A1 (en) * 2002-11-22 2004-05-27 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
EP1620072B1 (en) * 2003-05-01 2008-03-26 LTT Bio-Pharma Co., Ltd. Zinc-containing sustained-release composition, its preparation, and method for producing the same
JP4762717B2 (ja) * 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
US20070184050A1 (en) * 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
CN101166763B (zh) 2005-04-18 2012-09-19 伊达研究和发展有限公司 稳定的抗乙肝病毒(hbv)抗体配制剂
GB0707938D0 (en) * 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
JP2009153392A (ja) * 2007-12-25 2009-07-16 Lion Corp 液体経口用組成物
BRPI0907186A2 (pt) * 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
RU2653753C1 (ru) * 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
GB0818228D0 (en) * 2008-10-06 2008-11-12 Avecia Biolog Ltd Purification process
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug

Also Published As

Publication number Publication date
ES2659981T3 (es) 2018-03-20
ZA201308841B (en) 2015-02-25
ZA201304446B (en) 2014-02-26
AR124676A2 (es) 2023-04-26
PT2658575T (pt) 2018-02-22
MX2013007537A (es) 2014-03-13
DK2658575T3 (en) 2018-01-22
RU2013133953A (ru) 2015-02-10
EP2471554A1 (en) 2012-07-04
JP2015131832A (ja) 2015-07-23
AU2011351414B2 (en) 2017-01-19
HRP20171931T1 (hr) 2018-02-23
CN103269718A (zh) 2013-08-28
EP2658575A1 (en) 2013-11-06
KR101808367B1 (ko) 2018-01-18
TW201302223A (zh) 2013-01-16
BR112013016770A2 (pt) 2016-10-11
WO2012089778A1 (en) 2012-07-05
CA2822859C (en) 2016-11-08
EP2658575B1 (en) 2017-11-15
TWI530295B (zh) 2016-04-21
US9480743B2 (en) 2016-11-01
SI2658575T1 (en) 2018-02-28
RU2587056C2 (ru) 2016-06-10
JP2014505682A (ja) 2014-03-06
NO2658575T3 (es) 2018-04-14
HUE035707T2 (en) 2018-05-28
US20130336968A1 (en) 2013-12-19
PL2658575T3 (pl) 2018-04-30
JP5767340B2 (ja) 2015-08-19
KR20130137653A (ko) 2013-12-17
CN103269718B (zh) 2016-02-10
AU2011351414A1 (en) 2013-07-04
CA2822859A1 (en) 2012-07-05
AR084627A1 (es) 2013-05-29

Similar Documents

Publication Publication Date Title
MX2013007537A (es) Formulacion farmaceutica que comprende una droga biofarmaceutica.
JOP20180103A1 (ar) مركب صيدلاني
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
MX2022007264A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
UA109010C2 (en) Morpholino pyrividines and their use in therapy
MY183312A (en) Pharmaceutical formulation
IN2015KN00262A (es)
EP3699176A3 (en) Antiviral compounds
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
EP2546330A4 (en) MILKY ACID BACTERIA CONTAINING PREPARATION
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
MX351599B (es) Polimeros cationicos con base en glucogeno.
IN2015DN03998A (es)
EP3228311A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
MX2012012993A (es) Composiciones de tetraciclina.
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
WO2010118291A3 (en) Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
IN2014DN10449A (es)
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
EP2641594A3 (en) Enteric coated solid pharmaceutical compositions for proton pump inhibitors
HUE040484T2 (hu) Eljárás (3S,3S')4,4'-diszulfándiilbisz(3-aminobután-1-szulfonsav) elõállítására

Legal Events

Date Code Title Description
FG Grant or registration